<\/strong><\/span><\/h4>\n<\/strong><\/span><\/h4>\n<\/strong><\/span><\/h4>\nLucian Miron MD, PhD<\/strong><\/span>
Regional Institute of Oncology Ia\u015fi<\/strong><\/span>
University of Medicine and Pharmacy “Grigore T. Popa” Iasi<\/strong><\/span><\/h4>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.25″][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.3.4″ hover_enabled=”0″]<\/p>\n
Dermatological sides effects on systemic therapies in cancer patients<\/span>
Author: Lucian Miron<\/span><\/p>\nIn the last decades, oncological treatments have undergone an important development through the emergence of new agents. Among the most common side effects of oncology therapies are skin changes called dermatological toxicities.
\nConventional cytotoxic chemotherapy continues to play an important role in cancer treatment. The most common post-chemotherapy skin adverse events are: hyperpigmentation, hand-foot syndrome, radiation use, hypersensitivity, extravasation lesions and nail dystrophies.
\nErythematous dermatitis and hyperpigmentation are associated with bleomycin treatment (20% -30% of patients), followed by \u201cAddison-like dermatitis, known as palmoplantar erythrodysesthesia, which may occur after treatment with agents such as capecitabine, doxorubicin, cibarabine, 5-Fluorouracil. Dermatological toxicities are rarely fatal, but they can cause significant morbidity, cosmetic disfigurement and psychological distress.
\nTyrosine kinase inhibitors (TKI). cetuximab, panitumumab, gefitinib, erlotinib, lapatinib), antiangiogenic agents, vascular endothelial growth factor receptor inhibitors \u2013 VEGFRi (eg, bevacizumab, sorafenib), mitogen-activated protein (MAPK) pathway inhibitors, such as RAF (eg, vemurafenib, dabrafenib), MEKi (eg, cobimetinib, trametinib); mTOR inhibitors (eg everolimus); multikinase inhibitors (eg, vandetanib, pazopanib, sunitinib) and hedgehog inhibitors (vismodegib) are examples of targeted molecular therapies.
\nTargeted molecular therapies may also cause pigmentation changes, such as yellow pigmentation in sunitinib (VEGFR inhibitor) treated patients, hypopigmentation (diffuse or localized) associated with imatinib treatment. EGFR inhibitors are frequently associated with frequent nail toxicity (17.2% of patients in a meta-analysis). Perioral fissures, paronychia and pyogenic granuloma lesions begin to develop two or more months after initiation of therapy.
\n.Pululopustular rash: also known as \u201cacne rash\u201d or \u201cfolliculitis\u201d, this is the most common dermatological toxicity after treatment with EGFR inhibitors (cetuximab). Other features that are present, especially after the treatment, are, periungual cracks and granulomas, xerosis, pruritus and altered prichomegaly hair, hypertricosis and non-scarring alopecia.
\nImmunotherapy uses the activation of the immune system to fight cancer! Recently, immunotherapy has become a new therapeutic alternative for cancer patients. Monoclonal antibody therapies such as checkpoint inhibitors such as: ipilimumab, nivolumab, pembrolizumab, atezolizumab, durvolumab and others have become commonplace in the treatment of an increasing number of cancers. One of the most common side effects of immunotherapy is skin toxicity. This is the most common and appears even the earliest at the beginning of treatment (rash and pruritus after first administration). Patients may have a common macular-papular rash, which often resembles a drug reaction or significant itching. Ihting can also occur without visible skin lesions. The most common skin effects occur in patients treated with CTLA4 inhibitors (ipilimumab 40% -60%) and anti PD-1 (nivolumab 25%) and PDL-1 (pembrolizumab, atezolizumab) usually develops at the beginning of treatment. The most common skin conditions are: rash, itching and vitiligo. Vitiligo is more common in patients treated for melanoma. Rare side effects include alopecia areata, stomatitis, dermal kerosis, photosensitivity, exacerbation of psoriasis, psoriziform or lichenioid skin reactions. From the histological point of view, the skin reactions can be classified into: inflammatory skin disorders, bullous, keratotic and melanic lesions.
\nLichenoid reactions: those rashes can develop on the skin and \/ or mucous membranes (orally and genitally). Oral involvement may also include xerostomia and taste change; psoriasis and rosacea: these agents may induce exacerbation or re-emergence of psoriasis, pemphigoid-type autoimmune diseases. Immunotherapy has been linked to vitiligo-like lesions, mainly, but not only to patients treated with
\nDermatological adverse events are one of the most common toxicities observed for cancer treatments. Although they rarely occur as manifestations that do not endanger the patient\u2019s life, they can lead to dose reduction or even discontinuation of oncological therapy, which interferes with the outcome of the disease.<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.19.4″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/primaderma.ro\/en\/wp-content\/uploads\/2019\/01\/back_justflowers_overlay1.png” background_blend=”luminosity” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” top_divider_height_tablet=”” top_divider_height_phone=”77px” top_divider_height_last_edited=”on|desktop” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical” bottom_divider_height_tablet=”” bottom_divider_height_phone=”54px” bottom_divider_height_last_edited=”on|desktop” global_module=”516″ saved_tabs=”all”][et_pb_row column_structure=”3_5,2_5″ _builder_version=”3.25″ custom_padding=”61px|0px|69px|0px|false|false”][et_pb_column type=”3_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.3.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark” text_line_height_tablet=”” text_line_height_phone=”1.2em” text_line_height_last_edited=”on|desktop”]<\/p>\n
Contact PDI 2020’s PCO<\/p>\n
[\/et_pb_text][et_pb_contact_form email=”contact@primaderma.ro” submit_button_text=”Send” _builder_version=”3.19.4″ title_font=”||||||||”][et_pb_contact_field field_id=”Name” field_title=”Name” _builder_version=”3.19.4″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”E-mail address” field_type=”email” _builder_version=”3.19.4″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Message” field_type=”text” fullwidth_field=”on” _builder_version=”3.19.4″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.3.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n
PCO of PDI 2020<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”4.3.4″ text_font=”||||||||”]<\/p>\n
![\"\"](\"https:\/\/primaderma.ro\/en\/wp-content\/uploads\/2019\/01\/eventer_logo_150px.png\")
<\/span><\/p>\n<\/span><\/p>\n<\/span><\/p>\nAddress: A. Panu St. no. 13, Iasi<\/span>
Tel.: +40 332.40.88.05<\/span>
E-mail: inscrieri@primaderma.ro<\/a>
<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a><\/p>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
[et_pb_section fb_built=”1″ fullwidth=”on” _builder_version=”3.22″ custom_margin=”||” custom_padding=”15px||29px” top_divider_style=”waves2″ top_divider_color=”#f0622a” top_divider_flip=”horizontal|vertical” bottom_divider_style=”waves2″ bottom_divider_color=”#fcdedb” bottom_divider_height=”105px” bottom_divider_flip=”vertical” collapsed=”off”][et_pb_fullwidth_header title=”@ET-DC@eyJkeW5hbWljIjp0cnVlLCJjb250ZW50IjoicG9zdF90aXRsZSIsInNldHRpbmdzIjp7ImJlZm9yZSI6IiIsImFmdGVyIjoiIn19@” text_orientation=”right” header_image_url=”https:\/\/primaderma.ro\/en\/wp-content\/uploads\/2020\/03\/pdi2020_new.png” disabled_on=”on|on|off” _builder_version=”4.3.4″ _dynamic_attributes=”title” title_font=”Kaushan Script||||||||” title_text_align=”right” title_text_color=”#f0622a” title_font_size=”50px” content_font=”|600||on|||||” content_text_align=”center” content_text_color=”#686766″ content_font_size=”15px” subhead_font=”||||||||” background_color=”rgba(239,145,107,0.54)” background_image=”https:\/\/primaderma.ro\/en\/wp-content\/uploads\/2019\/01\/back.jpg” background_layout=”light” custom_margin=”0px||8px” custom_padding=”40px||40px||true” content_font_size_tablet=”” content_font_size_phone=”15px” content_font_size_last_edited=”on|desktop”][\/et_pb_fullwidth_header][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row column_structure=”2_5,3_5″ _builder_version=”3.25″][et_pb_column type=”2_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_image src=”https:\/\/primaderma.ro\/en\/wp-content\/uploads\/2020\/05\/Miron-Lucian.png” align=”center” align_tablet=”center” align_phone=”” align_last_edited=”on|desktop” _builder_version=”4.3.4″ max_width=”35%” border_radii=”on|100px|100px|100px|100px”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_5″ […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"_links":{"self":[{"href":"https:\/\/pdi.ro\/en\/wp-json\/wp\/v2\/pages\/5233"}],"collection":[{"href":"https:\/\/pdi.ro\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pdi.ro\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/en\/wp-json\/wp\/v2\/comments?post=5233"}],"version-history":[{"count":7,"href":"https:\/\/pdi.ro\/en\/wp-json\/wp\/v2\/pages\/5233\/revisions"}],"predecessor-version":[{"id":8246,"href":"https:\/\/pdi.ro\/en\/wp-json\/wp\/v2\/pages\/5233\/revisions\/8246"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/en\/wp-json\/wp\/v2\/media?parent=5233"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
<\/strong><\/span><\/h4>\nLucian Miron MD, PhD<\/strong><\/span>
Regional Institute of Oncology Ia\u015fi<\/strong><\/span>
University of Medicine and Pharmacy “Grigore T. Popa” Iasi<\/strong><\/span><\/h4>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.25″][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.3.4″ hover_enabled=”0″]<\/p>\n
Dermatological sides effects on systemic therapies in cancer patients<\/span>
Author: Lucian Miron<\/span><\/p>\nIn the last decades, oncological treatments have undergone an important development through the emergence of new agents. Among the most common side effects of oncology therapies are skin changes called dermatological toxicities.
\nConventional cytotoxic chemotherapy continues to play an important role in cancer treatment. The most common post-chemotherapy skin adverse events are: hyperpigmentation, hand-foot syndrome, radiation use, hypersensitivity, extravasation lesions and nail dystrophies.
\nErythematous dermatitis and hyperpigmentation are associated with bleomycin treatment (20% -30% of patients), followed by \u201cAddison-like dermatitis, known as palmoplantar erythrodysesthesia, which may occur after treatment with agents such as capecitabine, doxorubicin, cibarabine, 5-Fluorouracil. Dermatological toxicities are rarely fatal, but they can cause significant morbidity, cosmetic disfigurement and psychological distress.
\nTyrosine kinase inhibitors (TKI). cetuximab, panitumumab, gefitinib, erlotinib, lapatinib), antiangiogenic agents, vascular endothelial growth factor receptor inhibitors \u2013 VEGFRi (eg, bevacizumab, sorafenib), mitogen-activated protein (MAPK) pathway inhibitors, such as RAF (eg, vemurafenib, dabrafenib), MEKi (eg, cobimetinib, trametinib); mTOR inhibitors (eg everolimus); multikinase inhibitors (eg, vandetanib, pazopanib, sunitinib) and hedgehog inhibitors (vismodegib) are examples of targeted molecular therapies.
\nTargeted molecular therapies may also cause pigmentation changes, such as yellow pigmentation in sunitinib (VEGFR inhibitor) treated patients, hypopigmentation (diffuse or localized) associated with imatinib treatment. EGFR inhibitors are frequently associated with frequent nail toxicity (17.2% of patients in a meta-analysis). Perioral fissures, paronychia and pyogenic granuloma lesions begin to develop two or more months after initiation of therapy.
\n.Pululopustular rash: also known as \u201cacne rash\u201d or \u201cfolliculitis\u201d, this is the most common dermatological toxicity after treatment with EGFR inhibitors (cetuximab). Other features that are present, especially after the treatment, are, periungual cracks and granulomas, xerosis, pruritus and altered prichomegaly hair, hypertricosis and non-scarring alopecia.
\nImmunotherapy uses the activation of the immune system to fight cancer! Recently, immunotherapy has become a new therapeutic alternative for cancer patients. Monoclonal antibody therapies such as checkpoint inhibitors such as: ipilimumab, nivolumab, pembrolizumab, atezolizumab, durvolumab and others have become commonplace in the treatment of an increasing number of cancers. One of the most common side effects of immunotherapy is skin toxicity. This is the most common and appears even the earliest at the beginning of treatment (rash and pruritus after first administration). Patients may have a common macular-papular rash, which often resembles a drug reaction or significant itching. Ihting can also occur without visible skin lesions. The most common skin effects occur in patients treated with CTLA4 inhibitors (ipilimumab 40% -60%) and anti PD-1 (nivolumab 25%) and PDL-1 (pembrolizumab, atezolizumab) usually develops at the beginning of treatment. The most common skin conditions are: rash, itching and vitiligo. Vitiligo is more common in patients treated for melanoma. Rare side effects include alopecia areata, stomatitis, dermal kerosis, photosensitivity, exacerbation of psoriasis, psoriziform or lichenioid skin reactions. From the histological point of view, the skin reactions can be classified into: inflammatory skin disorders, bullous, keratotic and melanic lesions.
\nLichenoid reactions: those rashes can develop on the skin and \/ or mucous membranes (orally and genitally). Oral involvement may also include xerostomia and taste change; psoriasis and rosacea: these agents may induce exacerbation or re-emergence of psoriasis, pemphigoid-type autoimmune diseases. Immunotherapy has been linked to vitiligo-like lesions, mainly, but not only to patients treated with
\nDermatological adverse events are one of the most common toxicities observed for cancer treatments. Although they rarely occur as manifestations that do not endanger the patient\u2019s life, they can lead to dose reduction or even discontinuation of oncological therapy, which interferes with the outcome of the disease.<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.19.4″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/primaderma.ro\/en\/wp-content\/uploads\/2019\/01\/back_justflowers_overlay1.png” background_blend=”luminosity” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” top_divider_height_tablet=”” top_divider_height_phone=”77px” top_divider_height_last_edited=”on|desktop” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical” bottom_divider_height_tablet=”” bottom_divider_height_phone=”54px” bottom_divider_height_last_edited=”on|desktop” global_module=”516″ saved_tabs=”all”][et_pb_row column_structure=”3_5,2_5″ _builder_version=”3.25″ custom_padding=”61px|0px|69px|0px|false|false”][et_pb_column type=”3_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.3.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark” text_line_height_tablet=”” text_line_height_phone=”1.2em” text_line_height_last_edited=”on|desktop”]<\/p>\n
Contact PDI 2020’s PCO<\/p>\n
[\/et_pb_text][et_pb_contact_form email=”contact@primaderma.ro” submit_button_text=”Send” _builder_version=”3.19.4″ title_font=”||||||||”][et_pb_contact_field field_id=”Name” field_title=”Name” _builder_version=”3.19.4″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”E-mail address” field_type=”email” _builder_version=”3.19.4″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Message” field_type=”text” fullwidth_field=”on” _builder_version=”3.19.4″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.3.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n
PCO of PDI 2020<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”4.3.4″ text_font=”||||||||”]<\/p>\n
<\/span><\/p>\n<\/span><\/p>\n<\/span><\/p>\nAddress: A. Panu St. no. 13, Iasi<\/span>
Tel.: +40 332.40.88.05<\/span>
E-mail: inscrieri@primaderma.ro<\/a>
<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a><\/p>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
[et_pb_section fb_built=”1″ fullwidth=”on” _builder_version=”3.22″ custom_margin=”||” custom_padding=”15px||29px” top_divider_style=”waves2″ top_divider_color=”#f0622a” top_divider_flip=”horizontal|vertical” bottom_divider_style=”waves2″ bottom_divider_color=”#fcdedb” bottom_divider_height=”105px” bottom_divider_flip=”vertical” collapsed=”off”][et_pb_fullwidth_header title=”@ET-DC@eyJkeW5hbWljIjp0cnVlLCJjb250ZW50IjoicG9zdF90aXRsZSIsInNldHRpbmdzIjp7ImJlZm9yZSI6IiIsImFmdGVyIjoiIn19@” text_orientation=”right” header_image_url=”https:\/\/primaderma.ro\/en\/wp-content\/uploads\/2020\/03\/pdi2020_new.png” disabled_on=”on|on|off” _builder_version=”4.3.4″ _dynamic_attributes=”title” title_font=”Kaushan Script||||||||” title_text_align=”right” title_text_color=”#f0622a” title_font_size=”50px” content_font=”|600||on|||||” content_text_align=”center” content_text_color=”#686766″ content_font_size=”15px” subhead_font=”||||||||” background_color=”rgba(239,145,107,0.54)” background_image=”https:\/\/primaderma.ro\/en\/wp-content\/uploads\/2019\/01\/back.jpg” background_layout=”light” custom_margin=”0px||8px” custom_padding=”40px||40px||true” content_font_size_tablet=”” content_font_size_phone=”15px” content_font_size_last_edited=”on|desktop”][\/et_pb_fullwidth_header][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row column_structure=”2_5,3_5″ _builder_version=”3.25″][et_pb_column type=”2_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_image src=”https:\/\/primaderma.ro\/en\/wp-content\/uploads\/2020\/05\/Miron-Lucian.png” align=”center” align_tablet=”center” align_phone=”” align_last_edited=”on|desktop” _builder_version=”4.3.4″ max_width=”35%” border_radii=”on|100px|100px|100px|100px”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_5″ […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"_links":{"self":[{"href":"https:\/\/pdi.ro\/en\/wp-json\/wp\/v2\/pages\/5233"}],"collection":[{"href":"https:\/\/pdi.ro\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pdi.ro\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/en\/wp-json\/wp\/v2\/comments?post=5233"}],"version-history":[{"count":7,"href":"https:\/\/pdi.ro\/en\/wp-json\/wp\/v2\/pages\/5233\/revisions"}],"predecessor-version":[{"id":8246,"href":"https:\/\/pdi.ro\/en\/wp-json\/wp\/v2\/pages\/5233\/revisions\/8246"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/en\/wp-json\/wp\/v2\/media?parent=5233"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Regional Institute of Oncology Ia\u015fi<\/strong><\/span>
University of Medicine and Pharmacy “Grigore T. Popa” Iasi<\/strong><\/span><\/h4>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.25″][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.3.4″ hover_enabled=”0″]<\/p>\n
Dermatological sides effects on systemic therapies in cancer patients<\/span> In the last decades, oncological treatments have undergone an important development through the emergence of new agents. Among the most common side effects of oncology therapies are skin changes called dermatological toxicities. [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.19.4″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/primaderma.ro\/en\/wp-content\/uploads\/2019\/01\/back_justflowers_overlay1.png” background_blend=”luminosity” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” top_divider_height_tablet=”” top_divider_height_phone=”77px” top_divider_height_last_edited=”on|desktop” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical” bottom_divider_height_tablet=”” bottom_divider_height_phone=”54px” bottom_divider_height_last_edited=”on|desktop” global_module=”516″ saved_tabs=”all”][et_pb_row column_structure=”3_5,2_5″ _builder_version=”3.25″ custom_padding=”61px|0px|69px|0px|false|false”][et_pb_column type=”3_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.3.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark” text_line_height_tablet=”” text_line_height_phone=”1.2em” text_line_height_last_edited=”on|desktop”]<\/p>\n Contact PDI 2020’s PCO<\/p>\n [\/et_pb_text][et_pb_contact_form email=”contact@primaderma.ro” submit_button_text=”Send” _builder_version=”3.19.4″ title_font=”||||||||”][et_pb_contact_field field_id=”Name” field_title=”Name” _builder_version=”3.19.4″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”E-mail address” field_type=”email” _builder_version=”3.19.4″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Message” field_type=”text” fullwidth_field=”on” _builder_version=”3.19.4″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.3.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n PCO of PDI 2020<\/p>\n [\/et_pb_text][et_pb_text _builder_version=”4.3.4″ text_font=”||||||||”]<\/p>\n <\/span><\/p>\n <\/span><\/p>\n Address: A. Panu St. no. 13, Iasi<\/span> [\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" [et_pb_section fb_built=”1″ fullwidth=”on” _builder_version=”3.22″ custom_margin=”||” custom_padding=”15px||29px” top_divider_style=”waves2″ top_divider_color=”#f0622a” top_divider_flip=”horizontal|vertical” bottom_divider_style=”waves2″ bottom_divider_color=”#fcdedb” bottom_divider_height=”105px” bottom_divider_flip=”vertical” collapsed=”off”][et_pb_fullwidth_header title=”@ET-DC@eyJkeW5hbWljIjp0cnVlLCJjb250ZW50IjoicG9zdF90aXRsZSIsInNldHRpbmdzIjp7ImJlZm9yZSI6IiIsImFmdGVyIjoiIn19@” text_orientation=”right” header_image_url=”https:\/\/primaderma.ro\/en\/wp-content\/uploads\/2020\/03\/pdi2020_new.png” disabled_on=”on|on|off” _builder_version=”4.3.4″ _dynamic_attributes=”title” title_font=”Kaushan Script||||||||” title_text_align=”right” title_text_color=”#f0622a” title_font_size=”50px” content_font=”|600||on|||||” content_text_align=”center” content_text_color=”#686766″ content_font_size=”15px” subhead_font=”||||||||” background_color=”rgba(239,145,107,0.54)” background_image=”https:\/\/primaderma.ro\/en\/wp-content\/uploads\/2019\/01\/back.jpg” background_layout=”light” custom_margin=”0px||8px” custom_padding=”40px||40px||true” content_font_size_tablet=”” content_font_size_phone=”15px” content_font_size_last_edited=”on|desktop”][\/et_pb_fullwidth_header][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row column_structure=”2_5,3_5″ _builder_version=”3.25″][et_pb_column type=”2_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_image src=”https:\/\/primaderma.ro\/en\/wp-content\/uploads\/2020\/05\/Miron-Lucian.png” align=”center” align_tablet=”center” align_phone=”” align_last_edited=”on|desktop” _builder_version=”4.3.4″ max_width=”35%” border_radii=”on|100px|100px|100px|100px”][\/et_pb_image][\/et_pb_column][et_pb_column type=”3_5″ […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"_links":{"self":[{"href":"https:\/\/pdi.ro\/en\/wp-json\/wp\/v2\/pages\/5233"}],"collection":[{"href":"https:\/\/pdi.ro\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pdi.ro\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/en\/wp-json\/wp\/v2\/comments?post=5233"}],"version-history":[{"count":7,"href":"https:\/\/pdi.ro\/en\/wp-json\/wp\/v2\/pages\/5233\/revisions"}],"predecessor-version":[{"id":8246,"href":"https:\/\/pdi.ro\/en\/wp-json\/wp\/v2\/pages\/5233\/revisions\/8246"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/en\/wp-json\/wp\/v2\/media?parent=5233"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Author: Lucian Miron<\/span><\/p>\n
\nConventional cytotoxic chemotherapy continues to play an important role in cancer treatment. The most common post-chemotherapy skin adverse events are: hyperpigmentation, hand-foot syndrome, radiation use, hypersensitivity, extravasation lesions and nail dystrophies.
\nErythematous dermatitis and hyperpigmentation are associated with bleomycin treatment (20% -30% of patients), followed by \u201cAddison-like dermatitis, known as palmoplantar erythrodysesthesia, which may occur after treatment with agents such as capecitabine, doxorubicin, cibarabine, 5-Fluorouracil. Dermatological toxicities are rarely fatal, but they can cause significant morbidity, cosmetic disfigurement and psychological distress.
\nTyrosine kinase inhibitors (TKI). cetuximab, panitumumab, gefitinib, erlotinib, lapatinib), antiangiogenic agents, vascular endothelial growth factor receptor inhibitors \u2013 VEGFRi (eg, bevacizumab, sorafenib), mitogen-activated protein (MAPK) pathway inhibitors, such as RAF (eg, vemurafenib, dabrafenib), MEKi (eg, cobimetinib, trametinib); mTOR inhibitors (eg everolimus); multikinase inhibitors (eg, vandetanib, pazopanib, sunitinib) and hedgehog inhibitors (vismodegib) are examples of targeted molecular therapies.
\nTargeted molecular therapies may also cause pigmentation changes, such as yellow pigmentation in sunitinib (VEGFR inhibitor) treated patients, hypopigmentation (diffuse or localized) associated with imatinib treatment. EGFR inhibitors are frequently associated with frequent nail toxicity (17.2% of patients in a meta-analysis). Perioral fissures, paronychia and pyogenic granuloma lesions begin to develop two or more months after initiation of therapy.
\n.Pululopustular rash: also known as \u201cacne rash\u201d or \u201cfolliculitis\u201d, this is the most common dermatological toxicity after treatment with EGFR inhibitors (cetuximab). Other features that are present, especially after the treatment, are, periungual cracks and granulomas, xerosis, pruritus and altered prichomegaly hair, hypertricosis and non-scarring alopecia.
\nImmunotherapy uses the activation of the immune system to fight cancer! Recently, immunotherapy has become a new therapeutic alternative for cancer patients. Monoclonal antibody therapies such as checkpoint inhibitors such as: ipilimumab, nivolumab, pembrolizumab, atezolizumab, durvolumab and others have become commonplace in the treatment of an increasing number of cancers. One of the most common side effects of immunotherapy is skin toxicity. This is the most common and appears even the earliest at the beginning of treatment (rash and pruritus after first administration). Patients may have a common macular-papular rash, which often resembles a drug reaction or significant itching. Ihting can also occur without visible skin lesions. The most common skin effects occur in patients treated with CTLA4 inhibitors (ipilimumab 40% -60%) and anti PD-1 (nivolumab 25%) and PDL-1 (pembrolizumab, atezolizumab) usually develops at the beginning of treatment. The most common skin conditions are: rash, itching and vitiligo. Vitiligo is more common in patients treated for melanoma. Rare side effects include alopecia areata, stomatitis, dermal kerosis, photosensitivity, exacerbation of psoriasis, psoriziform or lichenioid skin reactions. From the histological point of view, the skin reactions can be classified into: inflammatory skin disorders, bullous, keratotic and melanic lesions.
\nLichenoid reactions: those rashes can develop on the skin and \/ or mucous membranes (orally and genitally). Oral involvement may also include xerostomia and taste change; psoriasis and rosacea: these agents may induce exacerbation or re-emergence of psoriasis, pemphigoid-type autoimmune diseases. Immunotherapy has been linked to vitiligo-like lesions, mainly, but not only to patients treated with
\nDermatological adverse events are one of the most common toxicities observed for cancer treatments. Although they rarely occur as manifestations that do not endanger the patient\u2019s life, they can lead to dose reduction or even discontinuation of oncological therapy, which interferes with the outcome of the disease.<\/p>\n<\/span><\/p>\n
Tel.: +40 332.40.88.05<\/span>
E-mail: inscrieri@primaderma.ro<\/a>
<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a><\/p>\n